OBJECTIVES: To estimate the utility-based quality of life (QOL) of people with chronic kidney disease (CKD) and to estimate the QOL associated with two hypothetical colorectal cancer health states. METHODS: A cross-sectional study was conducted in people with CKD (stages 3-5, transplant recipients and those on dialysis) from three centres in Sydney, Australia. We measured participants' own QOL and that of two hypothetical colorectal cancer health states using a rating scale, and a utility-based QOL measure, the time trade-off, with extremes of 0 (death) and 1 (full health). RESULTS: Recipients of kidney transplants (n=79) had the highest mean QOL weights of 0.79 (standard deviation (SD)=0.34) compared with participants with CKD 3-5 (n=53) with mean QOL weights of 0.70 (SD=0.39), and those on dialysis (n=89), who had the lowest mean QOL weights of 0.62 (SD=0.41) (P=0.02). Having early and advanced stage colorectal cancers were valued at mean QOL weights of 0.44 (SD=0.41) and 0.12 (SD=0.25) among people with moderate stage CKD; 0.45 (SD=0.39) and 0.11 (SD=0.24) among dialysis patients; 0.62 (SD=0.36) and 0.18 (SD=0.29) among kidney transplant recipients. CONCLUSIONS: People with CKD have poor QOL. Having coexistent illnesses such as cancer further reduces the overall well-being of individuals with kidney disease. In addition to the development of effective screening and treatment programs to improve cancer outcomes in people with CKD, our study also highlights the need for effective interventions to improve the QOL in people with CKD, particularly those with major comorbidities like cancer.
OBJECTIVES: To estimate the utility-based quality of life (QOL) of people with chronic kidney disease (CKD) and to estimate the QOL associated with two hypothetical colorectal cancer health states. METHODS: A cross-sectional study was conducted in people with CKD (stages 3-5, transplant recipients and those on dialysis) from three centres in Sydney, Australia. We measured participants' own QOL and that of two hypothetical colorectal cancer health states using a rating scale, and a utility-based QOL measure, the time trade-off, with extremes of 0 (death) and 1 (full health). RESULTS: Recipients of kidney transplants (n=79) had the highest mean QOL weights of 0.79 (standard deviation (SD)=0.34) compared with participants with CKD 3-5 (n=53) with mean QOL weights of 0.70 (SD=0.39), and those on dialysis (n=89), who had the lowest mean QOL weights of 0.62 (SD=0.41) (P=0.02). Having early and advanced stage colorectal cancers were valued at mean QOL weights of 0.44 (SD=0.41) and 0.12 (SD=0.25) among people with moderate stage CKD; 0.45 (SD=0.39) and 0.11 (SD=0.24) among dialysis patients; 0.62 (SD=0.36) and 0.18 (SD=0.29) among kidney transplant recipients. CONCLUSIONS:People with CKD have poor QOL. Having coexistent illnesses such as cancer further reduces the overall well-being of individuals with kidney disease. In addition to the development of effective screening and treatment programs to improve cancer outcomes in people with CKD, our study also highlights the need for effective interventions to improve the QOL in people with CKD, particularly those with major comorbidities like cancer.
Authors: Anoushka Krishnan; Armando Teixeira-Pinto; Wai H Lim; Kirsten Howard; Jeremy R Chapman; Antoni Castells; Simon D Roger; Michael J Bourke; Petra Macaskill; Gabrielle Williams; Charmaine E Lok; Fritz Diekmann; Nicholas Cross; Shaundeep Sen; Richard D M Allen; Steven J Chadban; Carol A Pollock; Robin Turner; Allison Tong; Jean Y H Yang; Narelle Williams; Eric Au; Anh Kieu; Laura James; Anna Francis; Germaine Wong; Jonathan C Craig Journal: Kidney Int Rep Date: 2020-10-03
Authors: Allison Tong; Braden Manns; Angela Yee Moon Wang; Brenda Hemmelgarn; David C Wheeler; John Gill; Peter Tugwell; Robert Pecoits-Filho; Sally Crowe; Tess Harris; Wim Van Biesen; Wolfgang C Winkelmayer; Adeera Levin; Aliza Thompson; Vlado Perkovic; Angela Ju; Talia Gutman; Amelie Bernier-Jean; Andrea K Viecelli; Emma O'Lone; Jenny Shen; Michelle A Josephson; Yeoungjee Cho; David W Johnson; Bénédicte Sautenet; Marcello Tonelli; Jonathan C Craig Journal: Kidney Int Date: 2018-10-22 Impact factor: 10.612
Authors: Gábor Kovács; Giovanna Devercelli; Tamás Zelei; Ishan Hirji; Zoltán Vokó; Paul A Keown Journal: PLoS One Date: 2020-04-28 Impact factor: 3.240
Authors: Allison Tong; Braden Manns; Brenda Hemmelgarn; David C Wheeler; Peter Tugwell; Wolfgang C Winkelmayer; Wim van Biesen; Sally Crowe; Peter G Kerr; Kevan R Polkinghorne; Kirsten Howard; Carol Pollock; Carmel M Hawley; David W Johnson; Stephen P McDonald; Martin P Gallagher; Rachel Urquhart-Secord; Jonathan C Craig Journal: Trials Date: 2015-08-19 Impact factor: 2.279